Evidence to Practice

We bring new evidence from clinical trials to the clinical community via educational activities, enabling informed uptake of new treatments and best practice.

[The Asia Pacific Cardiometabolic Consortium @the_apcmc]

Congratulations to our member @WannJiaLoh for hosting a Lp(a) #Awareness Day in conjunction with Changi General Hospital (CGH).
Her goal was to 'unpack the who, what, why and how's of #lipoprotein(a).'

Find out more information about Dr Wann’s initiative https://t.co/hQGpRdrWLk

[The Asia Pacific Cardiometabolic Consortium @the_apcmc]

This Thursday, 16th March at 8.00pm AEDT via @apsc_office @ProfSNicholls will summarise the results from the CLEAR Outcomes trial. Join Steve and our panel as we discuss this important trial and the new option it presents for patients with statin intolerance.

[Evidence to Practice @evi2prac]

Join us at our annual Symposium to discuss the latest topical and developing areas in cardiology! Tickets are going fast so register today.

[Evidence to Practice @evi2prac]

Our Webinar will be held on Tuesday, 20th September from 7.00pm - 8.30pm and is free to attend.

[Evidence to Practice @evi2prac]

If you're after a breakdown of the major Clinical Trials presented at ESC 2022 - we've got you covered!

Register for tickets and join our expert faculty as we discuss the major implications of these results for practice in Australia.
https://t.co/SeDARTTTec

[Evidence to Practice @evi2prac]

Further investigation needed into the potential for Asundexian as a safer anticoagulant in an adequately powered phase 3 clinical trial

[Evidence to Practice @evi2prac]

PACIFIC-AMI demonstrating that Asundexian 50mg daily on top of DAPT resulted in near complete (>90%) inhibition of factor Xla inhibition following acute MI #ESCCongress

[Evidence to Practice @evi2prac]

On top of DAPT there was no increase in significant (BARC 2,3 or 5) or any bleeding with any dose of Asundexian compared with placebo

[Evidence to Practice @evi2prac]

The INVICTUS study showing that in RHD-AF, compared to rivaroxaban,VKAs have a lower mortality and reduced ischemic stroke without increasing the risk of major bleeding. VKAs should remain the standard of care in RHD-AF

[NEJM @NEJM]

DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO

[Evidence to Practice @evi2prac]

ALL-HEART - Allopurinol added to usual care did not improve outcomes in patients aged over 60 years with IHD (but no gout) #ESCCongress

[Evidence to Practice @evi2prac]

Nor did PCI incrementally improve left ventricular ejection fraction or provide a sustained difference in quality of life

[Evidence to Practice @evi2prac]

The REVIVED study (Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction) demonstrating that patients with ischaemic cardiomyopathy continue to have high rates of mortality and hospitalisation for HF even with contemporary medical and device therapy.

[Evidence to Practice @evi2prac]

PCI did not reduce the composite incidence of all-cause mortality or hospitalisation for heart failure at a median of 3.4 years.

[Evidence to Practice @evi2prac]

This study as well as other recent RCTs and observational data point to the potential for influenza vaccination to be standard practice at discharge for CVD.

[Evidence to Practice @evi2prac]

The DANFLU-1 trial (High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults) demonstrates that the incidence of hospitalisation for influenza or pneumonia was significantly lower in the QIV-HD group compared to the QIV-SD group.

[Evidence to Practice @evi2prac]

The role of high dose flu vaccine in CVD is unresolved however likely the best choice for those 65 years +

[Evidence to Practice @evi2prac]

The results of ADVOR highlight the importance of targeting congestion both early and aggressively and support the use of natriuresis as an indicator or diuretic response.

[Evidence to Practice @evi2prac]

ADVOR (Acetazolamide in Acute Decompensated Heart Failure with Volume OveRload) demonstrating that the addition of 500mg IV acetazolamide to standardised IV loop diuretic was associated with a 46% higher incidence of successful decongestion after 3 days. #ESCCongress

[Evidence to Practice @evi2prac]

Subgroup analyses indicate that the younger age group (65-69 years) may benefit from screening

[Evidence to Practice @evi2prac]

DANCAVAS - Screening and intervention to prevent cardiovascular disease. After 5 years, an invitation for comprehensive imaging based CV screening did not significantly reduce all cause mortality among men aged 65-74 years #ESCCongress